Decibel Therapeutics, Inc. - DBTX STOCK NEWS

Decibel Therapeutics (Nasdaq: DBTX) has appointed Cynthia Hu as the new Chief Legal Officer and Corporate Secretary. With over 20 years of experience, including 15 years in the life sciences sector, Hu previously served at CASI Pharmaceuticals as Chief Operating Officer. Her expertise is expected to support Decibel's ambitions in developing transformative treatments for hearing and balance disorders, particularly gene therapies for congenital hearing loss. This strategic move comes as the company aims to establish itself as a leader in this critical area of healthcare.

Decibel Therapeutics (Nasdaq: DBTX) reported a productive second quarter of 2021, announcing key appointments to its Board and Scientific Advisory Board, including Dr. William H. Carson as Chairman. The company is on track to achieve significant milestones in 2022, including the submission of an IND for its DB-OTO program and interim analysis for the DB-020 Phase 1b trial for cisplatin-induced hearing loss. As of June 30, 2021, Decibel's cash position was $184.6 million, significantly up from $54.3 million at the end of 2020, providing financial stability for its ongoing developments.

Decibel Therapeutics (Nasdaq: DBTX) announces the appointment of William (Bill) H. Carson, M.D. as Chairman of the Board, effective June 2, 2021. Dr. Carson brings over 20 years of biopharmaceutical leadership experience, having recently served as the President and CEO of Otsuka Pharmaceutical Development. He has a successful track record in therapy development, regulatory approvals, and commercialization. His appointment highlights Decibel's commitment to advancing innovative therapies for hearing and balance disorders, leveraging a proprietary platform aimed at addressing significant unmet medical needs.

Decibel Therapeutics (Nasdaq: DBTX) announced new appointments to its Scientific Advisory Board on May 24, 2021, enhancing its expertise in gene therapy, cochlear development, and molecular genetics. Notable members include Connie Cepko, Guangping Gao, Matthew Kelley, Glenn Pierce, and Dinah Sah. Their combined experience is aimed at advancing Decibel's gene therapy programs targeting hearing loss and balance disorders. The company is focused on unmet needs in these fields, leveraging its proprietary platform for revolutionary treatments.

BOSTON, May 19, 2021 – Decibel Therapeutics (Nasdaq: DBTX) announced that CEO Laurence Reid, Ph.D., will present at the UBS Global Healthcare Virtual Conference on May 26, 2021, at 7:00 am ET. A live webcast will be available on the Company's Investor website, with an archived replay for 90 days post-event. Decibel specializes in transformative treatments for hearing and balance disorders, leveraging innovative gene therapy technologies to address significant unmet medical needs.

Decibel Therapeutics (Nasdaq: DBTX) reported significant financial developments on May 13, 2021. They established a cGMP manufacturing agreement with Catalent for their lead gene therapy, DB-OTO, and successfully completed a Series D financing alongside an upsized IPO, raising approximately $165.3M. As of March 31, 2021, their cash and equivalents soared to $191.1M. Research expenses dropped to $6.0M, while general and administrative expenses increased to $4.9M. The company anticipates advancing its clinical programs and expects to submit an IND application in 2022.

Decibel Therapeutics (Nasdaq: DBTX) announced its participation in the ASGCT 24th Annual Meeting, with two digital presentations scheduled for May 11, 2021. The presentations will feature data on DB-OTO, a gene therapy developed in collaboration with Regeneron Pharmaceuticals to address otoferlin gene deficiencies in children. Key details include:

• Abstract 579: Focuses on preclinical data for DB-OTO.
• Abstract 536: Discusses AAV toxicity mechanisms in the ear.

Decibel aims to transform treatments in hearing and balance, addressing significant unmet medical needs.

Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company focused on hearing and balance treatments, announced that CEO Laurence Reid, Ph.D., will present at the Needham Virtual Healthcare Conference on April 15, 2021, at 4:30 PM ET.

A live webcast can be accessed via the Investors and Media section of their website, with an archived replay available for 90 days post-presentation.

Decibel is advancing gene therapies for congenital and acquired hearing loss, leveraging a proprietary platform that includes precision gene therapy technologies.

Decibel Therapeutics (Nasdaq: DBTX) successfully completed a $220.1M oversubscribed Series D financing and upsized IPO, enhancing its financial position. The company established a key partnership with Catalent for developing its lead gene therapy, DB-OTO, while launching the Amplify™ genetic testing program in collaboration with Invitae. DB-020 received Fast Track designation from the FDA. The company presented significant preclinical data at the ARO conference. For the year ended December 31, 2020, Decibel reported cash and equivalents of $54.3M, reflecting strong funding capabilities for future initiatives.